Press Release FeedGet the RSS feed
Menu

Business Wire

Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026

Bayer

Presentations include investigational late-breaking KERENDIA® (finerenone) data in chronic kidney disease (CKD), including a pooled analysis from studies in patients with and without diabetes and a subanalysis in patients with CKD without diabetes, and for iodine 124 evuzamitide (I 124 evuzamitide) from a Phase III study in patients with suspected cardiac amyloidosis.

WHIPPANY, N.J., August 20, 2026--Bayer

Summary

Bayer today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, from August 28-31, 2026.

Key Facts

  • Data from two late-breaking presentations will be featured, including a pre-specified subgroup analysis from the Phase III FIND-CKD trial, which evaluated KERENDIA® (finerenone) in patients with CKD without diabetes and hypertensive nephropathy, and data from the INFINITY pooled analysis evaluating the efficacy and safety of KERENDIA in patients with chronic kidney disease (CKD) with and without a history of atherosclerotic cardiovascular disease (ASCVD). Additional subanalysis data will also be presented for KERENDIA in people living with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40%.

  • KERENDIA is currently approved by the FDA for use in adults with CKD associated with type 2 diabetes (T2D), as well as adults with HF with LVEF ≥40%.

  • Full results from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based on visual scan interpretation, will be shared for the first time.

  • A new analysis from the previously presented Phase III OCEANIC-STROKE trial will explore how participant characteristics affected their response to asundexian in secondary stroke prevention.

Why This Matters

"Bayer is committed to further researching and providing resources to support prevention, early diagnosis, and management for people with heart and kidney conditions, as well as stroke. These data reflect Bayer's commitment to that cause," said Robert Perkins, MD, Vice President, US Medical Affairs. "We look forward to advancing the scientific dialogue across the spectrum of cardiovascular and cerebrovascular disease care."

BAYER PRESENTATIONS AT ESC 2026:

Cardiac Amyloidosis

  • A phase 3, open-label, multicenter study of investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide in the assessment of patients with suspected cardiac amyloidosis

    • Session: Late-Breaking Clinical Science: cardiac amyloidosis

      • August 30, 2026, 1:45 PM CEST to 2:00 PM CEST, Achgabat (Hall A3)

  1. IndustrialBayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United StatesCompanies: BayerNEW ALBANY, Ohio, October 02, 2026--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S.
  2. AIBayer to Present How it Rebuilt Global Planning with OMP at Gartner Supply Chain Planning Summit 2026Companies: BayerANTWERPEN, BELGIUM, Sept 17, 2026 - OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Planning Summit 2026 in London to its joint session with multinational Bayer. Representatives of the Pharmaceutical division and the global IT department will show what it took to rebuild global planning around faster, higher-quality decisions, how Unison Planning™ supports that at scale, and where AI fits in. Rebuilding planning at Bayer's scale Bayer treated its move to Unison Planning™ as more than a system replacement, rebuilding processes, master data, and ways of working across its global manufacturing and affiliate network. During their Gartner session, Mirja Meyer, Principal Product Manager and Program Lead IT at Bayer, and Karsten Hahm, Program Lead OMP Implementation at Bayer Pharmaceuticals, will cover: What adoption actually took What changed in decision speed and quality Where AI fits on the roadmap ahead Sign up for the session Why planning leaders should attend AI-driven planning is on every agenda. Bayer's session addresses the part that usually goes unsaid: what a planning organization needs in place before an AI implementation survives the test of a real supply chain. Meet OMP and explore what it means to make decisions at the speed of change Throughout the Gartner Supply Chain Planning Summit (Oct 5-6, London), OMP is present at booth 203, demonstrating how Unison Planning™ and UnisonIQ help organizations move toward always-on supply chain orchestration. See how integrated planning, enhanced by the latest AI advancements, drives faster scenario evaluation, stronger collaboration, and measurable business results. Join OMP at Gartner to hear Bayer's journey firsthand and leave with a clearer path to faster, more confident supply chain decisions. Session at a glance Title: Inside Bayer's Global Planning Rebuild and AI Roadmap - Faster Decisions at Scale Speakers: Mirja Meyer, Principal Product Manager, Program Lead IT, Bayer Karsten Hahm, Program Lead OMP Implementation, Bayer Pharmaceuticals When: Tuesday, October 6, 11:15 - 11:45 AM GMT+1 / 12:15 - 12:45 PM CEST Where: InterContinental London - The O2, London, United Kingdom To see where you can meet OMP next, visit our events calendar. About OMP OMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics, tires, and building products - benefit from using OMP's unique Unison Planning™. Solution and product inquiries Contact OMP +32 3 650 22 11 Media inquiries Kira Perdue (Carabiner) SOURCE: OMP
  3. Apollo Global Management, Inc. NEW YORK andApollo Funds Complete €3 Billion Capital Solution for BayerCompanies: Apollo Global ManagementBayerKKR & Co.KKR joins Apollo as a minority participant
  4. Food & drinkPhosalone Insecticide Market Outlook 2026-2030 Featuring Profiles of Leading Companies Bayer, Syngenta and UPLCompanies: BayerOpportunities center on Asia-Pacific and high-value crops, driven by food demand, precision farming, IPM, safer broad-spectrum products and controlled-release formulations.
  5. HealthcareBayerBayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026Companies: BayerWHIPPANY, N.J., August 30, 2026--Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the diagnosis of cardiac amyloidosis ba
  6. EnergyMarket One Media Group Inc.Market One: MustGrow Biologics Receives First Bayer Milestone PaymentCompanies: BayerMarket One ("Market One"), a marketing agency for public companies, shares editorial and video features on emerging growth stories across the resource, energy, and technology sectors.Market One delivers content creation and distribution through a suite of products across video, editorial, and social media.MustGrow Biologics Corp.: Advancing biocontrol technology commercializationMustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF)...